Financial Data and Key Metrics Changes - The company reported an underlying EBITDA of $20 million for FY '25, with operating cash flow also at $20 million and reduced debt levels to $67.7 million [23][34] - The total FY '25 dividend was $1.45 per share, representing a gross fully imputed dividend of $2.01 per share, which is 47% of AFFO, aligning with the target payout ratio of 40% to 70% [21][34] Business Line Data and Key Metrics Changes - Radius Care operates 24 aged care homes and four retirement villages, focusing on high acuity aged residential care and health services [12][13] - The company acquired the 109-bed St. Elisa care home in Christchurch for just under $1.1 million, expected to contribute to earnings from the second half of FY '26 [14][15] - CBIZ Catering Limited, acquired in October 2024, contributed $4.1 million in revenue and $500,000 in EBITDA for the period from October 2024 to March 2025 [15][16] Market Data and Key Metrics Changes - Occupancy rates are currently over 95%, with the latest figure at 95.8% [13][32] - The company has expanded into in-home care services, addressing the needs of New Zealand's aging population [17] Company Strategy and Development Direction - The company is in growth mode, focusing on capital light acquisitions, revenue diversification, and extending home opportunities [14][20] - The updated capital management framework aims to support reinvestment in core operating assets while maintaining sustainable dividend growth [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for growth across key financial metrics in FY '26, including underlying EBITDA and AFFO [21][35] - The company anticipates strong trading performance, with an upgraded guidance for underlying EBITDA in the first half of FY '26 to be between $14 million and $16 million [33] Other Important Information - The company has a strong focus on staff training and well-being, with a Net Promoter Score of 74 for facility managers, indicating high employee engagement [26][28] - The company has developed RadPro, an operational template that supports resident-centric decision-making and continuous improvement [18][39] Q&A Session Summary Question: Can you provide more details on RadPro and its development? - RadPro is the operating system developed over 21 years, encompassing all aspects of operations, including staff education and efficiency tools. It is now being expanded into home care services and has potential for marketing outside New Zealand [38][40]

Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Core Insights - Radiopharm Theranostics is advancing its clinical pipeline with significant milestones, including FDA Fast Track Designation for RAD101 and clearance for higher dosing of RAD204 [3][5][6] - The company confirmed a cash runway extending through mid-2026, with a year-end cash balance of $29.12 million, up from $18.58 million the previous year [10][12] Program and Business Updates - RAD204, a nanobody targeting PD-L1, is on track for higher dosing at 60mCi of Lu177, with enrollment for the second cohort expected to complete soon [6] - RAD202, targeting HER2, has initiated its Phase 1 HEAT trial, with preliminary data anticipated by the end of 2025 [6] - The company has established supply agreements for key radioisotopes, enhancing its clinical trial capabilities [3][12] Financial Update - For the fiscal year ending June 30, 2025, net cash outflows from operating activities totaled $36.67 million, primarily due to research and development expenditures [10][12] - The company received $4.58 million for research and development tax incentives for the 2024 financial year [12]

Core Viewpoint - Rite Aid is closing an additional 114 stores as part of its second bankruptcy proceedings in less than two years, driven by mounting debt, sluggish sales, and competition in the pharmacy industry [1][3][4]. Group 1: Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy protection in May 2023, just eight months after exiting its first bankruptcy [2][4]. - The bankruptcy court in New Jersey approved the closure of 114 stores, with the majority located in Pennsylvania [1][2][7]. - The company has already closed 154 stores as part of its store optimization plan, reducing its footprint to approximately 1,245 locations [3][4]. Group 2: Financial Challenges - Rite Aid emerged from its first bankruptcy with $2.5 billion in liabilities, indicating ongoing financial struggles [4]. - The company has faced increased competition from other pharmacy chains such as Walgreens, CVS, Walmart, and Amazon, which has contributed to its financial difficulties [4][6]. Group 3: Industry Context - Industry experts anticipate further closures across the pharmacy sector as companies adjust to market demands and rightsize their operations [6]. - The rapid expansion of pharmacy locations has outpaced the actual need for pharmacies, leading to financial strain on companies like Rite Aid [6].

Core Insights - Radiopharm Theranostics has completed the preclinical data package for RAD 402, an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic, and is preparing to initiate a Phase 1 clinical trial for prostate cancer in the second half of 2025 [1][2][3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumors, including lung, breast, and brain cancers [5] Partnership and Development - A supply agreement has been signed with Cyclotek to radiolabel RAD 402 with Terbium-161 (Tb), which is crucial for the upcoming Phase 1 clinical trial [1][3] - Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, will produce and provide doses of Tb-labeled RAD 402 [6][4] Therapeutic Focus - RAD 402 is designed to target KLK3, which is highly expressed in prostate tissue, potentially leading to improved therapeutic efficacy due to the unique properties of Tb compared to other radionuclides [2][4] - The partnership aims to enhance patient outcomes by improving the accessibility of radiopharmaceuticals [7][8]

Core Insights - The FDA has granted Fast Track Designation for RAD101, a novel imaging small molecule developed by Radiopharm Theranostics, aimed at distinguishing between recurrent disease and treatment effects in brain metastases from solid tumors [1][3] - RAD101 targets fatty acid synthase (FASN), which is overexpressed in many solid tumors, including cerebral metastases, potentially improving diagnostic precision for over 300,000 patients diagnosed annually in the U.S. [2][3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [6] - The company has a pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumor cancers, including lung, breast, and brain metastases [6] Clinical Trial Details - The Phase 2b clinical trial of RAD101 is a multicenter, open-label study evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases [4] - The primary objective is to assess the concordance between 18F-RAD101 positive lesions and those identified through conventional imaging (MRI with gadolinium) [4] - Secondary endpoints include the accuracy, sensitivity, and specificity of RAD101 in differentiating tumor recurrence from radiation necrosis in previously treated brain metastases [4] Product Information - RAD101 is designed to allow for more accurate detection of cancer cells by targeting FASN activity, representing a clinically relevant method for imaging brain metastases [5] - Positive data from a Phase 2a imaging trial indicated significant tumor uptake independent of the tumor's origin, suggesting potential for non-invasive prediction of overall survival [5]

Core Insights - Rite Aid is nearing a June 18 deadline for bidding on its remaining assets, with potential buyers including Walgreens, Kourtney Kardashian, private equity firms, and brand management companies [1][3] - The company filed for bankruptcy in May, marking its second filing in three years, primarily due to high debt, inflationary pressures, and competition [4][5] Group 1: Bankruptcy and Asset Sale - Rite Aid operates 1,200 stores and has over $2 billion in debt, facing challenges from inflation and lower consumer demand [4][5] - A bankruptcy judge has approved store closures and the sale of customer prescription files to CVS Health, Walmart, and others [3] - Rite Aid is pursuing a strategic sale process for substantially all of its assets, with a focus on maximizing value [5] Group 2: Store Closures and Sales - The company has targeted 210 store closures, with 95 locations revealed on May 19 [6] - Agreements have been reached to sell prescription files for over 1,000 pharmacy locations, with CVS, Walgreens, and others as successful bidders [6][7] - CVS plans to purchase prescription files for 625 locations and take over 64 physical Rite Aid stores [7]

Core Insights - The company has initiated the Phase 1 'HEAT' clinical trial for RAD202, targeting HER2-positive advanced solid tumors, marking a significant milestone in its transition to a clinical-stage entity [1][3][4] - The trial aims to assess the safety, tolerability, and preliminary efficacy of 177Lu-RAD202, with the first patient already dosed [2][3] - RAD202 is a proprietary nanobody that has shown promise in previous studies for treating HER2-positive cancers, including breast cancer [3][5] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [5] - The company is listed on ASX (RAD) and NASDAQ (RADX) and has a diverse pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumors [5] - The company aims to provide therapeutic options that improve clinical outcomes for patients with HER2-positive metastatic cancers [3][4]

Core Insights - Radiopharm Theranostics is advancing its RV01 program towards a first-in-human therapeutic basket study targeting solid tumor cancers, with an Investigational New Drug submission planned for mid-2025 and Phase 1 study initiation expected in Q4 2025 [1][7] Group 1: RV01 Program Development - The RV01 therapy is a B7-H3-targeted radiopharmaceutical designed to target solid tumors expressing the B7-H3 protein, which is associated with poor prognosis in various cancers [2] - Preclinical data indicates that RV01 demonstrates favorable biodistribution and high tumor uptake, with modifications in the Fc region leading to a shorter half-life compared to traditional monoclonal antibodies [1][3] - The antibody's faster liver excretion allows for effective tumor targeting while potentially reducing associated toxicities, offering advantages over traditional excretion methods [4] Group 2: Preclinical Data and Efficacy - New preclinical data supports earlier findings of RV01's strong affinity for the cancer-specific 4Ig isoform of the B7-H3 receptor, showing complete regression of established solid tumors and evidence of immune system stimulation [6] - The biodistribution study is the final preclinical work required for the IND application with the U.S. FDA, confirming the timeline for submission and study initiation [7] Group 3: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals, with a diverse pipeline including peptides, small molecules, and monoclonal antibodies for cancer treatment [9]

Core Insights - Rite Aid is closing additional stores and transferring business to competitors as it faces financial difficulties, having filed for bankruptcy for the second time [1][3] - The company plans to shut down 210 stores, with over 70 closures in Pennsylvania alone [1] - Rite Aid has reached agreements to sell prescription files for more than 1,000 pharmacy locations to major competitors like CVS and Walgreens [2] Group 1: Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy protection on May 5, 2023, less than a year after emerging from a previous restructuring effort [3] - The company previously attempted to reduce approximately $2 billion in debt and closed around 850 stores [3] - Rite Aid's current bankruptcy filing indicates ongoing financial struggles, leading to the decision to close additional locations [1][3] Group 2: Market Adaptation and Consumer Behavior - The company is adapting its offerings and pricing strategies to cater to paycheck-to-paycheck consumers, acknowledging the economic situation of its shoppers [5] - Rite Aid's difficulties are partly attributed to lower-income shoppers' trade-down behavior, with a shift towards purchasing household goods from more affordable retailers [6] - Research indicates that a significant majority of consumers change their purchasing behaviors during economic distress, with only 16% stating that perceived inflation has not affected their consumption [7]